Literature DB >> 23791826

Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.

Hyun Hoon Chung1, Inki Lee, Hee Seung Kim, Jae Weon Kim, Noh-Hyun Park, Yong Sang Song, Gi Jeong Cheon.   

Abstract

OBJECTIVE: Tumor metabolic activity is a significant prognostic factor for endometrial cancer; however, there are few reports on the clinical importance of metabolic tumor volume (MTV) in patients with endometrial cancer. Therefore, we evaluated the prognostic value of preoperative MTV measured by (18)F-FDG PET/CT and MRI in a group of these patients.
METHODS: We retrospectively reviewed patients with pathologically proven endometrial cancer who had undergone preoperative (18)F-FDG PET/CT and MRI scans. The prognostic significance of PET/CT parameters and other clinicopathological variables was evaluated.
RESULTS: A total of 76 consecutive patients were included in the study. The median follow-up duration was 27 mo (range 3 to 96 mo) after surgery. MTV was correlated with FIGO stage and SUVmax. Age and FIGO stage were independent prognostic factors for recurrence in the multivariate analysis. In the subgroup analysis for 62 patients with endometrioid endometrial cancer, age (hazard ratio 1.098, P = 0.007, 95% confidence interval (CI) 1.026-1.175) and an MTV index of ≥ 876.4 (hazard ratio 5.795, P = 0.032, 95% CI 1.160-28.958) were determined to be independent prognostic factors of recurrence, and there was a statistically significant difference in progression-free survival (PFS) between patients in the high MTV and low MTV groups (log-rank test, P = 0.002).
CONCLUSION: Preoperative MTV of the primary tumor was an independent prognostic factor for PFS and was significantly associated with recurrence in patients with endometrioid endometrial cancer. MTV is a promising tool for the prediction of outcome in patients with endometrioid endometrial cancer.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Endometrial cancer; Metabolic tumor volume; Preoperative; Prognostic factor

Mesh:

Substances:

Year:  2013        PMID: 23791826     DOI: 10.1016/j.ygyno.2013.06.021

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  12 in total

1.  Preoperative risk stratification using metabolic parameters of (18)F-FDG PET/CT in patients with endometrial cancer.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Yoshiko Ueno; Tetsuo Maeda; Yasuhiko Ebina; Hideto Yamada; Takashi Okunaga; Kazuhiro Kubo; Keitarou Sofue; Tomonori Kanda; Yukihisa Tamaki; Kazuro Sugimura
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-04-02       Impact factor: 9.236

2.  Preoperative PET/CT does not accurately detect extrauterine disease in patients with newly diagnosed high-risk endometrial cancer: A prospective study.

Authors:  Katherine I Stewart; Beth Chasen; William Erwin; Nicole Fleming; Shannon N Westin; Shayan Dioun; Michael Frumovitz; Pedro T Ramirez; Karen H Lu; Franklin Wong; Thomas A Aloia; Pamela T Soliman
Journal:  Cancer       Date:  2019-06-21       Impact factor: 6.860

3.  Usefulness of MRI-assisted metabolic volumetric parameters provided by simultaneous (18)F-fluorocholine PET/MRI for primary prostate cancer characterization.

Authors:  Yong-Il Kim; Gi Jeong Cheon; Jin Chul Paeng; Jeong Yeon Cho; Cheol Kwak; Keon Wook Kang; June-Key Chung; Euishin Edmund Kim; Dong Soo Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-03-11       Impact factor: 9.236

4.  Prognostic impact of primary tumor SUVmax on preoperative 18F-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography in endometrial cancer and uterine carcinosarcoma.

Authors:  Tamaki Yahata; Shigetaka Yagi; Yasushi Mabuchi; Yuko Tanizaki; Aya Kobayashi; Madoka Yamamoto; Mika Mizoguchi; Sakiko Nanjo; Michihisa Shiro; Nami Ota; Sawako Minami; Masaki Terada; Kazuhiko Ino
Journal:  Mol Clin Oncol       Date:  2016-08-04

5.  Prognostic value of total lesion glycolysis on preoperative 18F-FDG PET/CT in patients with uterine carcinosarcoma.

Authors:  Jeong-Won Lee; Eun Jin Heo; Seung Hwan Moon; Hyunjong Lee; Gi Jeong Cheon; Maria Lee; Hee Seung Kim; Hyun Hoon Chung
Journal:  Eur Radiol       Date:  2016-02-16       Impact factor: 5.315

Review 6.  What's New in Imaging for Gynecologic Cancer?

Authors:  Sairah R Khan; Mubarik Arshad; Kathryn Wallitt; Victoria Stewart; Nishat Bharwani; Tara D Barwick
Journal:  Curr Oncol Rep       Date:  2017-11-06       Impact factor: 5.075

7.  Development of a PET/CT molecular radiomics-clinical model to predict thoracic lymph node metastasis of invasive lung adenocarcinoma ≤ 3 cm in diameter.

Authors:  Cheng Chang; Maomei Ruan; Bei Lei; Jian Feng; Wenhui Xie; Hong Yu; Wenlu Zhao; Yaqiong Ge; Shaofeng Duan; Wenjing Teng; Qianfu Wu; Xiaohua Qian; Lihua Wang; Hui Yan; Ciyi Liu; Liu Liu
Journal:  EJNMMI Res       Date:  2022-04-21       Impact factor: 3.434

8.  Prediction of Recurrence by Preoperative Intratumoral FDG Uptake Heterogeneity in Endometrioid Endometrial Cancer.

Authors:  Seo Young Kang; Gi Jeong Cheon; Maria Lee; Hee Seung Kim; Jae-Weon Kim; Noh-Hyun Park; Yong Sang Song; Hyun Hoon Chung
Journal:  Transl Oncol       Date:  2017-02-03       Impact factor: 4.243

9.  Comparison of novel multi-level Otsu (MO-PET) and conventional PET segmentation methods for measuring FDG metabolic tumor volume in patients with soft tissue sarcoma.

Authors:  Inki Lee; Hyung-Jun Im; Meiyappan Solaiyappan; Steve Y Cho
Journal:  EJNMMI Phys       Date:  2017-09-18

10.  Prognostic value of metabolic parameters determined by preoperative ¹⁸F-FDG PET/CT in patients with uterine carcinosarcoma.

Authors:  Hyun Ju Lee; Jong Jin Lee; Jeong Yeol Park; Jong Hyeok Kim; Yong Man Kim; Young Tak Kim; Joo Hyun Nam
Journal:  J Gynecol Oncol       Date:  2017-07       Impact factor: 4.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.